Beximco Pharmaceuticals Limited
Pioneering Bangladeshi generic medicine exporter listed on the Dhaka Stock Exchange and London Stock Exchange AIM, holding USFDA, TGA Australia, and GCC health approvals.
Manufactured Products & Services
Sectors & Client Industries
Corporate Overview
Beximco Pharmaceuticals Limited (Beximco Pharma) is a premier formulation developer and generic medicine exporter based in Dhaka, Bangladesh. Commencing operations in 1980 as part of Beximco Group, the company achieved historic milestones by becoming the first Bangladeshi pharmaceutical entity to list on the London Stock Exchange Alternative Investment Market (AIM: BXP) in 2005.
In 2015, Beximco Pharma became the first manufacturer in Bangladesh to secure United States Food and Drug Administration (USFDA) approval for its solid oral dosage manufacturing facility in Tongi, followed by the first commercial shipment of prescription carvedilol tablets directly to the US generic market.
Manufacturing Infrastructure & Technology
Operating out of its 22-acre manufacturing campus in Tongi, Gazipur, Beximco Pharma features specialized manufacturing lines:
- Oral Solid Dosage (OSD) Facility: USFDA and TGA Australia compliant high-speed tableting and encapsulation suites with automated in-line weight check systems.
- Specialized Respiratory Plant: CFC-free Hydrofluoroalkane (HFA) metered-dose inhalers and dry powder inhalers supplying patients with chronic obstructive pulmonary disease (COPD) and asthma.
- Sterile Ophthalmic Unit: Automated cleanrooms with form-fill-seal (FFS) technology producing preservative-free eye drop suspensions.
Strategic Acquisitions & Market Outreach
Through its majority acquisition of Sanofi Bangladesh (rebranded as Synovia Pharma PLC), Beximco Pharma significantly strengthened its domestic footprint in cardiology, central nervous system disorders, and essential vaccines. Today, Beximco generic products are registered across more than 50 countries globally.
Sources, Data & References
In accordance with BD Market Insights Editorial Standards, all factual claims, market sizes, and corporate data cited in this publication are cross-referenced with official filings, regulatory bodies, and industry documentation.
- London Stock Exchange (AIM: BXP) Listed Entity Disclosures — londonstockexchange.com (Accessed: September 28, 2026)
- Beximco Pharmaceuticals Ltd Annual Audited Reports — beximcopharma.com (Accessed: September 28, 2026)
Entity Verification Policy
BD Market Insights publishes verified corporate profiles derived from public regulatory filings, direct corporate statements, and established industry documentation. We do not accept paid compensation for profile placement or rankings.
Read our selection criteria →